• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia.联合 CDK9/BET 抑制在 MLL 重排急性白血病的临床前模型中的疗效。
Blood Adv. 2020 Jan 28;4(2):296-300. doi: 10.1182/bloodadvances.2019000586.
2
The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.CDK9 抑制剂 Dinaciclib 在 MLL 重排的急性髓系白血病的临床前模型中发挥强大的凋亡和抗肿瘤作用。
Cancer Res. 2016 Mar 1;76(5):1158-69. doi: 10.1158/0008-5472.CAN-15-1070. Epub 2015 Dec 1.
3
CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.CDKI-73：一种口服生物利用度高且高效的 CDK9 抑制剂，用于治疗急性髓系白血病。
Invest New Drugs. 2019 Aug;37(4):625-635. doi: 10.1007/s10637-018-0661-2. Epub 2018 Sep 8.
4
Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models.在临床前急性髓细胞白血病模型中发现一种新型、高选择性 CDK9 激酶抑制剂（JSH-009），具有强大的抗肿瘤疗效。
Invest New Drugs. 2020 Oct;38(5):1272-1281. doi: 10.1007/s10637-019-00868-3. Epub 2019 Dec 23.
5
ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.锌指蛋白521维持MLL重排急性髓系白血病中的分化阻滞。
Oncotarget. 2017 Apr 18;8(16):26129-26141. doi: 10.18632/oncotarget.15387.
6
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.靶向克服 MLL 重排白血病分化阻滞的抑制剂的功能多样性。
J Hematol Oncol. 2019 Jun 28;12(1):66. doi: 10.1186/s13045-019-0749-y.
7
Aberrant TRPM4 expression in MLL-rearranged acute myeloid leukemia and its blockade induces cell cycle arrest via AKT/GLI1/Cyclin D1 pathway.异常表达的 TRPM4 在 MLL 重排的急性髓系白血病中的作用及其通过 AKT/GLI1/Cyclin D1 通路诱导细胞周期停滞。
Cell Signal. 2020 Aug;72:109643. doi: 10.1016/j.cellsig.2020.109643. Epub 2020 Apr 19.
8
Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.在MLL重排的急性髓系白血病中，menin与MLL1/MLL2影响的不同通路。
Exp Hematol. 2019 Jan;69:37-42. doi: 10.1016/j.exphem.2018.10.001. Epub 2018 Oct 10.
9
Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.MLL重排白血病中MLL融合/MYC⊣miR-26⊣TET1信号通路的鉴定
Cancer Lett. 2016 Mar 28;372(2):157-65. doi: 10.1016/j.canlet.2015.12.032. Epub 2016 Jan 11.
10
An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in -rearranged acute myeloid leukemia in mice.异常持续的应急粒细胞生成反应加速了小鼠中 - 重排急性髓系白血病化疗后的复发。
J Biol Chem. 2020 Jul 10;295(28):9663-9675. doi: 10.1074/jbc.RA120.013206. Epub 2020 May 28.

引用本文的文献

1
Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer.细胞周期蛋白依赖性激酶作为前列腺癌异常转录的介质
Transl Oncol. 2025 May;55:102378. doi: 10.1016/j.tranon.2025.102378. Epub 2025 Mar 30.
2
Histone methyltransferase KMT2A: Developmental regulation to oncogenic transformation.组蛋白甲基转移酶 KMT2A：从发育调控到致癌转化。
J Biol Chem. 2024 Oct;300(10):107791. doi: 10.1016/j.jbc.2024.107791. Epub 2024 Sep 18.
3
CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.CDK9抑制作用可抑制前列腺癌中的多种致癌转录和表观遗传途径。
Br J Cancer. 2024 Oct;131(6):1092-1105. doi: 10.1038/s41416-024-02810-8. Epub 2024 Aug 8.
4
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.多激酶抑制剂地西他滨通过抑制Wnt/β-连环蛋白信号通路逆转急性髓系白血病中对溴结构域和额外末端结构域（BET）抑制剂的耐药性。
Exp Hematol Oncol. 2024 Mar 4;13(1):27. doi: 10.1186/s40164-024-00483-w.
5
Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors.利用小分子BRD4和CDK9抑制剂联合对缺乏半胱天冬酶-8表达的高级别浆液性卵巢癌细胞进行协同致敏以增强化疗效果
Cancers (Basel). 2023 Dec 24;16(1):107. doi: 10.3390/cancers16010107.
6
Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment.用于急性髓系白血病治疗的激酶抑制剂联合疗法
Hematol Rep. 2023 May 24;15(2):331-346. doi: 10.3390/hematolrep15020035.
7
Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.在肿瘤治疗中靶向 CDK9 的选择性抑制剂或降解剂：最新进展概述。
Cancer Biol Ther. 2023 Dec 31;24(1):2219470. doi: 10.1080/15384047.2023.2219470.
8
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives.髓系白血病发生机制：当前观点与治疗目标。
Blood Rev. 2023 Jan;57:100996. doi: 10.1016/j.blre.2022.100996. Epub 2022 Aug 2.
9
Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms.浆细胞样树突状细胞，髓系肿瘤中的一个新靶点。
Cancers (Basel). 2022 Jul 21;14(14):3545. doi: 10.3390/cancers14143545.
10
Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer.转录相关细胞周期蛋白依赖性激酶作为前列腺癌的治疗靶点。
Oncogene. 2022 Jun;41(24):3303-3315. doi: 10.1038/s41388-022-02347-1. Epub 2022 May 14.

本文引用的文献

1
Rewiring the Epigenetic Networks in -Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions.重排白血病中表观遗传网络的重塑：表观遗传失调与药物干预
Front Cell Dev Biol. 2019 May 15;7:81. doi: 10.3389/fcell.2019.00081. eCollection 2019.
2
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.急性早幼粒细胞白血病的治疗：欧洲白血病网专家小组的最新建议。
Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25.
3
The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer.MYC增强子组：癌症中MYC的远程转录调控
Trends Cancer. 2018 Dec;4(12):810-822. doi: 10.1016/j.trecan.2018.10.003. Epub 2018 Nov 2.
4
CDK9: a signaling hub for transcriptional control.细胞周期蛋白依赖性激酶9：转录调控的信号枢纽
Transcription. 2019 Apr;10(2):57-75. doi: 10.1080/21541264.2018.1523668. Epub 2018 Oct 11.
5
CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.CDKI-73：一种口服生物利用度高且高效的 CDK9 抑制剂，用于治疗急性髓系白血病。
Invest New Drugs. 2019 Aug;37(4):625-635. doi: 10.1007/s10637-018-0661-2. Epub 2018 Sep 8.
6
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.新型 BET 溴结构域抑制剂 BI 894999 抑制超增强子相关转录，并与 AML 中的 CDK9 抑制协同作用。
Oncogene. 2018 May;37(20):2687-2701. doi: 10.1038/s41388-018-0150-2. Epub 2018 Mar 1.
7
A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies.一个 Myc 增强子簇调节正常和白血病造血干细胞层级。
Nature. 2018 Jan 25;553(7689):515-520. doi: 10.1038/nature25193. Epub 2018 Jan 17.
8
Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors.联合抑制BRD4和CDK9作为恶性横纹肌样瘤的一种新治疗方法。
Oncotarget. 2017 Jun 21;8(49):84986-84995. doi: 10.18632/oncotarget.18583. eCollection 2017 Oct 17.
9
The MLL recombinome of acute leukemias in 2017.2017 年急性白血病的 MLL 重排组。
Leukemia. 2018 Feb;32(2):273-284. doi: 10.1038/leu.2017.213. Epub 2017 Jul 13.
10
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.

联合 CDK9/BET 抑制在 MLL 重排急性白血病的临床前模型中的疗效。

Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia.

机构信息

Children's Cancer Institute, School of Women's and Children's Health, University of New South Wales Sydney, Sydney, NSW, Australia.

Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.

出版信息

Blood Adv. 2020 Jan 28;4(2):296-300. doi: 10.1182/bloodadvances.2019000586.

DOI:10.1182/bloodadvances.2019000586
PMID:31971998
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6988396/
Abstract

Cyclin-dependent kinase 9 and bromodomain and extraterminal inhibitors are synergistic in MLL-rearranged leukemia. Multiple AML driver genes are downregulated by the combined therapy suggesting broad applicability for this subtype.

摘要

周期蛋白依赖性激酶 9 和溴结构域和末端外显子抑制剂在 MLL 重排白血病中具有协同作用。联合治疗下调了多种 AML 驱动基因，表明该亚型具有广泛的适用性。